The U.S. Food and Drug Administration (FDA) has granted, for the first time, full, traditional approval for an Alzheimer’s medication that is designed to do more than treat the symptoms of the memory-robbing disease.
The drug, lecanemab (brand name Leqembi), was shown in clinical trials to help slow the progression of , which affects more than 6.5 million older Americans and for which there is no cure.
No comments:
Post a Comment